Autoantibodies as diagnostic and prognostic markers in systemic lupus erythematosus: An immunopathological review.

Robert J. Singh*

Clinical Pathology Services, Cleveland Clinic Foundation, Cleveland, OH, USA

Introduction

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multisystem involvement, fluctuating disease activity, and complex immunopathology. A hallmark feature of SLE is the presence of a wide range of autoantibodies that target nuclear, cytoplasmic, and cell surface antigens. These autoantibodies not only serve as key diagnostic markers but also provide valuable prognostic insights, making them essential tools in the clinical management of SLE.

The production of autoantibodies in SLE results from a breakdown in self-tolerance mechanisms, leading to an exaggerated immune response against self-antigens. B cells play a central role in this process, both as antigen-presenting cells and antibody-producing plasma cells. Autoreactive T-helper cells further drive B-cell activation, class switching, and affinity maturation, resulting in a diverse array of high-affinity autoantibodies.

Among the most widely recognized autoantibodies in SLE are **antinuclear antibodies (ANAs)**, present in over 95% of patients. Although not specific to SLE, the presence of ANA is a necessary screening tool. More disease-specific markers include **anti-double-stranded DNA (anti-dsDNA)** and **anti-Smith (anti-Sm)** antibodies. Anti-dsDNA antibodies are highly specific for SLE and correlate strongly with disease activity, especially in lupus nephritis. Fluctuations in their titers often precede clinical exacerbations, making them useful for monitoring disease progression [1-5].

Anti-Sm antibodies, while less sensitive, are highly specific for SLE and are included in the classification criteria established by the American College of Rheumatology (ACR) and the Systemic Lupus International Collaborating Clinics (SLICC). Other important autoantibodies include **anti-Ro/SSA** and **anti-La/SSB**, which are associated with subtypes of lupus such as cutaneous lupus and neonatal lupus. Their presence may also indicate a higher risk of photosensitivity and congenital heart block in newborns of affected mothers [6-10].

The immunopathological consequences of autoantibody production are significant. Many of these autoantibodies form immune complexes that deposit in tissues such as the kidneys, skin, joints, and central nervous system. These deposits activate the complement system and recruit inflammatory cells, resulting in tissue damage. Low complement levels (C3 and C4) are often observed in active disease and can serve as additional prognostic markers when evaluated alongside autoantibody profiles.

Beyond diagnosis and prognosis, autoantibody profiling helps in tailoring therapy. For instance, patients with high anti-dsDNA titers and low complement levels may benefit from immunosuppressive agents such as mycophenolate mofetil or cyclophosphamide. Additionally, monitoring these markers can help clinicians assess response to treatment and detect early signs of flare.

Recent advances in immunopathology and molecular diagnostics have led to the development of multiplex assays and high-sensitivity detection platforms. These technologies allow simultaneous quantification of multiple autoantibodies, enhancing diagnostic accuracy and enabling personalized approaches to SLE management.

Conclusion

In conclusion, autoantibodies play a central role in the immunopathology of SLE and serve as invaluable diagnostic and prognostic tools. Their identification and monitoring provide critical insights into disease activity, organ involvement, and therapeutic response, making them integral to modern SLE care and research.

References

1. Stoccoro A, Coppedè F. Role of epigenetics in Alzheimer's disease pathogenesis. Neurodegener. Dis. Manag. 2018;8(3):181-93.
2. Zeng Z, Mukherjee A, Zhang H. From genetics to epigenetics, roles of epigenetics in inflammatory bowel disease. Front. genet. 2019;10:1017.
3. Villeneuve LM, Natarajan R. The role of epigenetics in the pathology of diabetic complications. Am. J. Physiol. Renal Physiol. 2010;299(1):F14-25.
4. Hornschuh M, Wirthgen E, Wolfien M. The role of epigenetic modifications for the pathogenesis of Crohn's disease. Clin. Epigenetics. 2021;13(1):108.
5. Giallongo S, Longhitano L, Denaro S, et al. The role of epigenetics in neuroinflammatory-driven diseases. Int. J. Mol. Sci. 2022;23(23):15218.

***Correspondence to:** Robert J. Clinical Pathology Services, Cleveland Clinic Foundation, Cleveland, OH, USA. E-mail: rsingh@ccfpath.org

***Received:** 10-Feb-2025, Manuscript No. AACPLM- 25-164066; **Editor assigned:** 11-Feb-2025, Pre QC No. AACPLM- 25-164066 (PQ); **Reviewed:** 15-Feb-2025, QC No. AACPLM-25-164066; **Revised:** 18-Feb-2025, Manuscript No. AACPLM- 25-164066 (R); **Published:** 27-Feb-2025, DOI: 10.35841/ aacplm-7.1.249*

***Citation:** Singh RJ. Autoantibodies as diagnostic and prognostic markers in systemic lupus erythematosus: An immunopathological review. J Clin Path Lab Med.2025;(7)1:249*

6. Higginson J. The role of the pathologist in environmental medicine and public health. Am. J. Pathol. 1977;86(2):460.
7. Adesina A, Chumba D, Nelson AM. Improvement of pathology in sub-Saharan Africa. Lancet Oncol. 2013;14(4):e152-7.
8. Hanzlick R. Medical examiners, coroners, and public health: a review and update. Arch. Path. Lab. 2006;130(9):1274-82.
9. McGuone D, Sinard J, Gill JR. Autopsy services and emergency preparedness of a tertiary academic hospital mortuary for the COVID-19 public health emergency: the Yale plan. Adv. Anat. Pathol. 2020;27(6):355-62.
10. Snow P, Powell M. Developmental language disorders and adolescent risk: A public-health advocacy role for speech pathologists?. Am J Speech Lang Pathol. 2004;6(4):221-9.